Memorial Day! 45% Off Premium Subscription Claim Offer ⏰ 0d 00h 00m 00s

Coherus BioSciences Earnings Calls

Q1 2025 Missed
-$0.350 (-12.90%)
Release date May 12, 2025
EPS estimate -$0.310
EPS actual -$0.350
EPS Surprise -12.90%
Revenue estimate 60.964M
Revenue actual 7.599M
Revenue Surprise -87.54%
Q4 2024 Missed
-$0.280 (-180.00%)
Release date Mar 10, 2025
EPS estimate -$0.100
EPS actual -$0.280
EPS Surprise -180.00%
Revenue estimate 60M
Revenue actual 54.144M
Revenue Surprise -9.76%
Q3 2024 Beat
-$0.0100 (90.00%)
Release date Nov 06, 2024
EPS estimate -$0.100
EPS actual -$0.0100
EPS Surprise 90.00%
Revenue estimate 43.877M
Revenue actual 70.774M
Revenue Surprise 61.30%
Q2 2024 Beat
-$0.140 (33.33%)
Release date Aug 08, 2024
EPS estimate -$0.210
EPS actual -$0.140
EPS Surprise 33.33%
Revenue estimate 61.37M
Revenue actual 64.979M
Revenue Surprise 5.88%

Last 4 Quarters for Coherus BioSciences

Below you can see how CHRS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Aug 08, 2024
Fiscal end date Jun 30, 2024
Price on release $1.29
EPS estimate -$0.210
EPS actual -$0.140
EPS surprise 33.33%
Date Price
Aug 02, 2024 $1.35
Aug 05, 2024 $1.32
Aug 06, 2024 $1.33
Aug 07, 2024 $1.24
Aug 08, 2024 $1.29
Aug 09, 2024 $1.43
Aug 12, 2024 $1.46
Aug 13, 2024 $1.44
Aug 14, 2024 $1.37
4 days before -4.44%
4 days after 6.20%
On release day 10.85%
Change in period 1.48%
Q3 2024 Beat
Release date Nov 06, 2024
Fiscal end date Sep 30, 2024
Price on release $0.724
EPS estimate -$0.100
EPS actual -$0.0100
EPS surprise 90.00%
Date Price
Oct 31, 2024 $0.745
Nov 01, 2024 $0.723
Nov 04, 2024 $0.670
Nov 05, 2024 $0.731
Nov 06, 2024 $0.724
Nov 07, 2024 $0.82
Nov 08, 2024 $0.82
Nov 11, 2024 $0.779
Nov 12, 2024 $0.82
4 days before -2.85%
4 days after 13.77%
On release day 13.29%
Change in period 10.54%
Q4 2024 Missed
Release date Mar 10, 2025
Fiscal end date Dec 31, 2024
Price on release $1.04
EPS estimate -$0.100
EPS actual -$0.280
EPS surprise -180.00%
Date Price
Mar 04, 2025 $1.05
Mar 05, 2025 $1.03
Mar 06, 2025 $1.00
Mar 07, 2025 $1.04
Mar 10, 2025 $1.04
Mar 11, 2025 $1.05
Mar 12, 2025 $0.98
Mar 13, 2025 $0.89
Mar 14, 2025 $0.92
4 days before -0.95%
4 days after -11.53%
On release day 0.96%
Change in period -12.37%
Q1 2025 Missed
Release date May 12, 2025
Fiscal end date Mar 31, 2025
Price on release $1.02
EPS estimate -$0.310
EPS actual -$0.350
EPS surprise -12.90%
Date Price
May 06, 2025 $0.93
May 07, 2025 $0.95
May 08, 2025 $0.99
May 09, 2025 $0.97
May 12, 2025 $1.02
May 13, 2025 $0.83
May 14, 2025 $0.790
May 15, 2025 $0.768
May 16, 2025 $0.761
4 days before 9.69%
4 days after -25.39%
On release day -19.11%
Change in period -18.16%

Coherus BioSciences Earnings Call Transcript Summary of Q1 2025

Coherus BioSciences Q1 2025 Earnings Call Summary for Investors

Key Highlights:

  1. Transition to Innovative Oncology Focus:
    • Coherus has completed its biosimilar divestitures and is now focusing on its innovative oncology pipeline, particularly the PD-1 inhibitor LOQTORZI and related proprietary products.
  2. LOQTORZI Performance:
    • LOQTORZI, an FDA-approved PD-1 inhibitor for metastatic recurrent nasopharyngeal carcinoma (NPC), is projected to generate $150 million to $200 million in annual sales over the next three years.
    • The company expects to cover commercial and R&D costs once quarterly revenues surpass $15 million.
  3. Commercial Strategy:
    • A recent restructuring of the sales force is complete, aimed at enhancing market penetration and education about LOQTORZI.
    • Demand for LOQTORZI grew by 15% in Q1, with positive feedback from physicians leading to increased patient starts.
    • The new NCCN guidelines position LOQTORZI as a preferred treatment in combination with chemotherapy, which the company is actively promoting to oncologists.
  4. Pipeline Developments:
    • Toripalimab (LOQTORZI): The company intends to expand its indications by working on combination therapies with other agents and collaborations with various partners.
    • CHS-114 (CCR8 cytolytic antibody) is progressing, with initial data suggesting it effectively depletes Tregs in the tumor microenvironment, which is promising for treating solid tumors.
    • Casdozokitug (anti-IL-27) is being evaluated in combination therapies for hepatocellular carcinoma and non-small cell lung cancer, with data expected in the first half of 2026.
  5. Financial Overview:
    • Revenue from LOQTORZI was stable at $7.3 million; however, ongoing operational improvements are expected to enhance growth.
    • The divestiture of UDENYCA is complete, providing Coherus with $483 million in upfront cash, and significant savings are anticipated from reduced headcount and operational costs.
    • The company expects to have about $200 million in net cash after the recent divestiture and plans to further repurchase convertible notes.
  6. Investment Strategy:
    • Coherus is positioned to leverage its unique profiling of LOQTORZI and ongoing pipeline advancements to generate revenue.
    • The focus is also on maintaining and expanding partnerships for clinical trials and indication expansion that require minimal upfront costs for Coherus.

Conclusion:

Coherus BioSciences is transitioning into a commercial-stage innovative oncology firm, with a clear strategy to enhance the reach and impact of its lead product, LOQTORZI. With a supportive market environment and planned initiatives, Coherus is focused on driving growth and expanding its pipeline opportunities. Investors should monitor upcoming data releases and trial outcomes that could significantly impact the company’s valuation and market position.

Coherus BioSciences Earnings History

Earnings Calendar

FAQ

When is the earnings report for CHRS?
Coherus BioSciences (CHRS) has scheduled its earnings report for Aug 14, 2025 after the markets close.

What is the CHRS price-to-earnings (P/E) ratio?
CHRS P/E ratio as of May 23, 2025 (TTM) is -0.669.

What is the CHRS EPS forecast?
The forecasted EPS (Earnings Per Share) for Coherus BioSciences (CHRS) for the first fiscal quarter 2025 is -$0.250.

What are Coherus BioSciences's retained earnings?
On its balance sheet, Coherus BioSciences reported retained earnings of $7.60 million for the latest quarter ending Mar 31, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT COHERUS BIOSCIENCES
Coherus BioSciences
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ...
GOLDEN STAR
Ticker Change Signal Date
UAA
$5.84
11.64% May 09
IIPR
$54.61
1.70% May 09
HBM
$7.41
14.44% May 05
PODD
$257.01
24.90% May 02
GT
$9.14
21.77% Mar 21

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE